Drug sensitivity test for advanced salivary gland cancer
Part of Cancer, Mouth & dental clinical trials.
This trial tests whether a laboratory-grown mini-tumor (organoid) from your biopsy can predict which drugs will work best for your recurrent or metastatic salivary gland cancer. You would need to provide a tumor sample and have adequate organ function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have recurrent or metastatic salivary gland cancer that has been confirmed by a biopsy or pathology report
- You have enough tumor tissue available to grow a mini-tumor in the lab
- You are up and about at least half the day (ECOG score 0-2) and expected to live more than 3 months
- Your blood counts, liver, kidney, and clotting function are within acceptable ranges
- You are not pregnant, breastfeeding, or planning to become pregnant during the study
- You do not have active hepatitis B or C, HIV, uncontrolled heart disease, or other serious conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a patient's own tumor cells grown in a lab to test which drugs are most likely to work against their cancer. It aims to help guide treatment choices for people with head and neck cancer that has come back or spread.
This trial uses a lab-grown mini-tumor (organoid) from your biopsy to test which chemotherapy drugs work best for your cancer before you have surgery. The goal is to personalize your treatment and improve outcomes.
This trial tests a new drug combination (MRG003 with or without putrelimab) for people with advanced salivary gland cancer that has EGFR protein. It aims to see if the treatment is safe and helps shrink tumors.
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
This trial tests a combination of a targeted antibody-drug and focused radiation for people with advanced or recurrent salivary gland cancer that has spread. It aims to see if this treatment can help control the disease when standard treatments have stopped working.
This study looks at immune cells and substances in blood, saliva, and stool from people with salivary gland cancer. The goal is to find markers that could help predict how the disease behaves.
Hear when a new Salivary Gland Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.